Exploring the dual role of B cells in solid tumors

• Verfasst von: Bao, Jiantong [VerfasserIn]
• Verfasst von: Betzler, Annika C. [VerfasserIn]
• Verfasst von: Heß, Jochen [VerfasserIn]
• Verfasst von: Brunner, Cornelia [VerfasserIn]
• Titel: Exploring the dual role of B cells in solid tumors
• Titelzusatz: implications for head and neck squamous cell carcinoma
• Verf.angabe: Jiantong Bao, Annika C. Betzler, Jochen Hess and Cornelia Brunner
• E-Jahr: 2023
• Jahr: 05 October 2023
• Umfang: 20 S.
• Illustrationen: Illustrationen
• Fussnoten: Veröffentlicht: 05. Oktober 2023 ; Gesehen am 04.01.2024
• Titel Quelle: Enthalten in: Frontiers in immunology
• Ort Quelle: Lausanne : Frontiers Media, 2010
• Jahr Quelle: 2023
• Band/Heft Quelle: (2023), online ahead of print
• ISSN Quelle: 1664-3224
• DOI: doi:10.3389/fimmu.2023.1233085
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Errata: Bao, Jiantong: Corrigendum: Exploring the dual role of B cells in solid tumors
• K10plus-PPN: 1877261041

Abstract

In the tumor milieu of head and neck squamous cell carcinoma (HNSCC), distinct B cell subpopulations are present, which exert either pro- or anti-tumor activities. Multiple factors, including hypoxia, cytokines, interactions with tumor cells, and other immune infiltrating lymphocytes (TILs), alter the equilibrium between the dual roles of B cells leading to cancerogenesis. Certain B cell subsets in the tumor microenvironment (TME) exhibit immunosuppressive function. These cells are known as regulatory B (Breg) cells. Breg cells suppress immune responses by secreting a series of immunosuppressive cytokines, including IL-10, IL-35, TGF-β, granzyme B, and adenosine or dampen effector TILs by intercellular contacts. Multiple Breg phenotypes have been discovered in human and mouse cancer models. However, when compartmentalized within a tertiary lymphoid structure (TLS), B cells predominantly play anti-tumor effects. A mature TLS contains a CD20+ B cell zone with several important types of B cells, including germinal-center like B cells, antibody-secreting plasma cells, and memory B cells. They kill tumor cells via antibody-dependent cytotoxicity and phagocytosis, and local complement activation effects. TLSs are also privileged sites for local T and B cell coordination and activation. Nonetheless, in some cases, TLSs may serve as a niche for hidden tumor cells and indicate a bad prognosis. Thus, TIL-B cells exhibit bidirectional immune-modulatory activity and are responsive to a variety of immunotherapies. In this review, we discuss the functional distinctions between immunosuppressive Breg cells and immunogenic effector B cells that mature within TLSs with the focus on tumors of HNSCC patients. Additionally, we review contemporary immunotherapies that aim to target TIL-B cells. For the development of innovative therapeutic approaches to complement T-cell-based immunotherapy, a full understanding of either effector B cells or Breg cells is necessary.